Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia

Overview of attention for article published in Cancer (0008543X), April 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 38,160 followers.

RT @tomleblancMD: MDS session: Initial concerns about #leukemia progression with TPO drug romiplostim didn't pan out: https://t.co/E21dAcWH…

MDS session: Initial concerns about #leukemia progression with TPO drug romiplostim didn't pan out: https://t.co/E21dAcWHRN #ASH15

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk...http://t.co/PIJsAIkQ3f

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.